LipoSeuticals said today that it closed a financing round for an undisclosed amount led by Hong Kong-based life sciences fund, Delos Capital. The company has developed a sugar-lipid polymer-based formulation, Sulocence, which boosts drug stability and solubility. LipoSeuticals said it is applying the drug delivery technology to the reformulation of an array of marketed specialty […]